Enfusion is a global, high-growth software-as-a-service, or SaaS, provider focused on transforming the investment management industry. Enfusion's solution is designed to eliminate technology and information barriers, empowering investment managers to confidently make and execute better-informed investment decisions in real time. Enfusion simplifies investment and operational workflows by unifying mission-critical systems and coalescing data into a single dataset resulting in a single source of truth. This allows stakeholders throughout the entire client organization to interact more effectively with one another across the investment management lifecycle. Designed for the cloud from inception, Enfusion provides a flexible and simplified end-to-end solution that allows investment managers to focus their time and resources on investment performance. This enables us to build long-term partnerships with its clients, offering a solution that is not only tailored to meet their business needs today, but has the depth and breadth of capability to support them as they grow or enter new markets or asset classes.
Company profile
Ticker
ENFN
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Microsoft • Oracle • Mobileye Global • Gen Digital • BlackBerry • Activision Blizzard • Vmware • Adobe • Ceridian HCM Holding • McAfee ...
SEC CIK
Corporate docs
Subsidiaries
Enfusion Ltd. LLC • Enfusion US 1, Inc. • Enfusion US 2, Inc. • Enfusion US 3, Inc. • Enfusion Systems UK Ltd • Enfusion HK Limited • Enfusion Software Limited • Enfusion Softech India Private Limited • Enfusion (Singapore) Pte. Ltd. • Enfusion do Brasil Tecnologia da Informacao Ltda ...
ENFN stock data
Analyst ratings and price targets
Current price
Average target
$10.50
Low target
$9.50
High target
$12.00
Goldman Sachs
Maintains
$9.50
B of A Securities
Downgraded
$10.00
Morgan Stanley
Upgraded
$12.00
Latest filings (excl ownership)
8-K
Enfusion Names Michael Spellacy as Board Chair and Non-Executive Director
11 Jan 23
8-K
Enfusion Names Oleg Movchan as Chief Executive Officer
22 Dec 22
8-K
Enfusion Appoints Brad Herring as New Chief Financial Officer
19 Dec 22
EFFECT
Notice of effectiveness
5 Dec 22
8-K
Enfusion Welcomes New Addition to Board of Directors
30 Nov 22
CORRESP
Correspondence with SEC
30 Nov 22
UPLOAD
Letter from SEC
30 Nov 22
8-K
Enfusion Announces Resignation of Chief Financial Officer
28 Nov 22
S-3
Shelf registration
18 Nov 22
10-Q
2022 Q3
Quarterly report
10 Nov 22
Latest ownership filings
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | |
|---|---|---|
| Revenue | ||
| Cost of revenue | ||
| Operating income | ||
| Operating margin | ||
| Net income | ||
| Net profit margin | ||
| Cash on hand | ||
| Change in cash | ||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 63.54 mm | 63.54 mm | 63.54 mm | 63.54 mm | 63.54 mm | 63.54 mm |
| Cash burn (monthly) | (no burn) | (no burn) | (no burn) | 25.61 mm | (no burn) | 24.96 mm |
| Cash used (since last report) | n/a | n/a | n/a | 108.15 mm | n/a | 105.39 mm |
| Cash remaining | n/a | n/a | n/a | -44.61 mm | n/a | -41.85 mm |
| Runway (months of cash) | n/a | n/a | n/a | -1.7 | n/a | -1.7 |
Institutional ownership, Q3 2022
| 13F holders | Current |
|---|---|
| Total holders | 69 |
| Opened positions | 14 |
| Closed positions | 13 |
| Increased positions | 15 |
| Reduced positions | 23 |
| 13F shares | Current |
|---|---|
| Total value | 1.77 bn |
| Total shares | 134.11 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| FTV Iv | 31.30 mm | $655.37 mm |
| ICONIQ Capital | 14.04 mm | $173.25 mm |
| ICONIQ Strategic Partners V | 14.04 mm | $0.00 |
| Oleg Movchan | 13.62 mm | $0.00 |
| Malherbe Investments | 11.87 mm | $248.57 mm |
| LRA Ventures | 11.87 mm | $248.57 mm |
| Dragoneer Investment | 6.49 mm | $80.09 mm |
| Hillhouse Capital Management | 4.98 mm | $0.00 |
| Hillhouse Capital Advisors | 4.98 mm | $61.39 mm |
| Werner Capital | 4.68 mm | $98.04 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 25 Jan 23 | Lorelei M. Skillman | Class A Common Stock | Payment of exercise | Dispose F | No | No | 11.88 | 184 | 2.19 k | 46,513 |
| 25 Jan 23 | Lorelei M. Skillman | Class A Common Stock | Grant | Acquire A | No | No | 0 | 483 | 0.00 | 46,697 |
| 25 Jan 23 | Lawrence E Leibowitz | Class A Common Stock | Grant | Acquire A | No | No | 0 | 7,238 | 0.00 | 64,839 |
| 25 Jan 23 | Dan Groman | Class A Common Stock | Payment of exercise | Dispose F | No | No | 11.88 | 9,219 | 109.52 k | 93,733 |
| 25 Jan 23 | Dan Groman | Class A Common Stock | Grant | Acquire A | No | No | 0 | 21,976 | 0.00 | 102,952 |
| 25 Jan 23 | Bronwen Bastone | Class A Common Stock | Payment of exercise | Dispose F | No | No | 11.88 | 218 | 2.59 k | 163,421 |
| 25 Jan 23 | Bronwen Bastone | Class A Common Stock | Grant | Acquire A | No | No | 0 | 638 | 0.00 | 163,639 |
| 25 Jan 23 | Steven M. Bachert | Class A Common Stock | Payment of exercise | Dispose F | No | No | 11.88 | 9,632 | 114.43 k | 190,332 |
| 25 Jan 23 | Steven M. Bachert | Class A Common Stock | Grant | Acquire A | No | No | 0 | 35,739 | 0.00 | 199,964 |
News
Goldman Sachs Maintains Neutral on Enfusion, Lowers Price Target to $9.5
26 Jan 23
Enfusion Names Michael Spellacy As Board Chair And Non-Executive Director
11 Jan 23
Benzinga's Top Ratings Upgrades, Downgrades For January 4, 2023
4 Jan 23
B of A Securities Downgrades Enfusion to Underperform, Lowers Price Target to $10
4 Jan 23
Morgan Stanley Upgrades Enfusion to Overweight, Lowers Price Target to $12
3 Jan 23
Press releases
Enfusion Names Michael Spellacy as Board Chair and Non-Executive Director
11 Jan 23
Enfusion Names Oleg Movchan as Chief Executive Officer
22 Dec 22
Enfusion Appoints Brad Herring as New Chief Financial Officer
19 Dec 22
Enfusion Welcomes New Addition to Board of Directors
30 Nov 22
Enfusion Announces Resignation of Chief Financial Officer
28 Nov 22